[go: up one dir, main page]

MA44020A - Composés antitumoraux - Google Patents

Composés antitumoraux

Info

Publication number
MA44020A
MA44020A MA044020A MA44020A MA44020A MA 44020 A MA44020 A MA 44020A MA 044020 A MA044020 A MA 044020A MA 44020 A MA44020 A MA 44020A MA 44020 A MA44020 A MA 44020A
Authority
MA
Morocco
Prior art keywords
antitumor compounds
antitumor
compounds
Prior art date
Application number
MA044020A
Other languages
English (en)
Other versions
MA44020B1 (fr
Inventor
Marchante María Del Carmen Cuevas
Solloso Andrés Francesch
Barrasa Valentín Martínez
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of MA44020A publication Critical patent/MA44020A/fr
Publication of MA44020B1 publication Critical patent/MA44020B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA44020A 2017-04-27 2018-04-27 Composés antitumoraux MA44020B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17382228 2017-04-27
EP17382497 2017-07-26

Publications (2)

Publication Number Publication Date
MA44020A true MA44020A (fr) 2018-10-31
MA44020B1 MA44020B1 (fr) 2019-08-30

Family

ID=62063080

Family Applications (2)

Application Number Title Priority Date Filing Date
MA44021A MA44021B1 (fr) 2017-04-27 2018-04-27 Composés antitumoraux
MA44020A MA44020B1 (fr) 2017-04-27 2018-04-27 Composés antitumoraux

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA44021A MA44021B1 (fr) 2017-04-27 2018-04-27 Composés antitumoraux

Country Status (39)

Country Link
US (5) US11332480B2 (fr)
EP (5) EP4101855B9 (fr)
JP (5) JP7186723B2 (fr)
KR (3) KR102492283B1 (fr)
CN (4) CN117865987A (fr)
AU (4) AU2018260314C1 (fr)
BR (1) BR112019022282A2 (fr)
CA (1) CA3061518A1 (fr)
CL (1) CL2019003057A1 (fr)
CO (1) CO2019011967A2 (fr)
CY (3) CY1121885T1 (fr)
DK (5) DK4101855T3 (fr)
EC (1) ECSP19083967A (fr)
ES (5) ES2944579T3 (fr)
FI (3) FI4047002T3 (fr)
HK (2) HK1255938B (fr)
HR (5) HRP20231233T1 (fr)
HU (5) HUE062032T2 (fr)
IL (3) IL270153B2 (fr)
JO (1) JOP20190254A1 (fr)
LT (5) LT3615544T (fr)
MA (2) MA44021B1 (fr)
MD (5) MD3395821T2 (fr)
ME (2) ME03467B (fr)
MX (3) MX392829B (fr)
MY (1) MY198004A (fr)
PH (1) PH12019550224A1 (fr)
PL (5) PL4047002T3 (fr)
PT (2) PT3395821T (fr)
RS (5) RS59174B1 (fr)
SA (1) SA523440283B1 (fr)
SG (2) SG10201913300YA (fr)
SI (5) SI4101855T1 (fr)
SM (5) SMT202300169T1 (fr)
TN (2) TN2019000210A1 (fr)
TW (3) TWI742273B (fr)
UY (1) UY37706A (fr)
WO (1) WO2018197663A1 (fr)
ZA (1) ZA201907119B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190254A1 (ar) * 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
TWI824043B (zh) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物
EP4061372A1 (fr) * 2019-11-21 2022-09-28 Pharma Mar, S.A. Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine
US20240131180A1 (en) * 2020-04-21 2024-04-25 Pharma Mar, S.A. Drug antibody conjugates
TW202144369A (zh) * 2020-04-26 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 海鞘素類衍生物及其製備方法與醫藥用途
CA3218171A1 (fr) 2021-05-19 2022-11-24 Carmen KAHATT Schemas posologiques pour l'ecubectedine
WO2024186263A1 (fr) * 2023-03-07 2024-09-12 Axcynsis Therapeutics Pte. Ltd. Conjugués anticorps-médicament comprenant de la trabectédine et des dérivés de lurbinectédine
WO2025077996A1 (fr) 2023-10-09 2025-04-17 Pharma Mar, S.A. Procédé de synthèse pour préparer des composés d'ectéinascidine
EP4563149A1 (fr) 2023-11-30 2025-06-04 Pharma Mar, S.A. Lurbinectedin, ecubectedin et un composé apparenté destinés à être utilisés dans le traitement de cancers de la peau
TW202532075A (zh) * 2024-02-08 2025-08-16 大陸商映恩生物製藥（蘇州）有限公司 海鞘素類化合物及其應用
WO2025228594A1 (fr) 2024-04-30 2025-11-06 Pharma Mar, S.A. Utilisation d'ecubectedin dans le traitement de cancers y compris dans une polythérapie avec de l'atézolizumab
WO2025228596A1 (fr) 2024-04-30 2025-11-06 Pharma Mar, S.A. Combinaison de pm14 et d'un inhibiteur de topoisomérase i dans le traitement du cancer
WO2025228595A1 (fr) 2024-04-30 2025-11-06 Pharma Mar, S.A. Utilisation du composé ia dans le traitement de cancers comprenant une polythérapie à l'atézolizumab
WO2025228597A1 (fr) 2024-04-30 2025-11-06 Pharma Mar, S.A. Combinaison du composé ia et d'un inhibiteur de la topoisomérase i dans le traitement du cancer
WO2025233522A1 (fr) 2024-05-10 2025-11-13 Pharma Mar, S.A. Procédé de synthèse d'ecteinascidine

Family Cites Families (220)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3205220A (en) 1961-10-26 1965-09-07 Lilly Co Eli Leurosidine and leurocristine and their production
US4762949A (en) 1979-06-20 1988-08-09 University Of Illinois Foundation Acyl and carbamimidoyl alkanediamines
GB2058047B (en) 1979-07-11 1983-09-21 Asahi Chemical Ind Amides and amidines
FR2461995A1 (fr) 1979-07-20 1981-02-06 Lcc Cice Cie Europ Compo Elect Transducteur magneto-electrique pour systeme d'enregistrement magnetique, et systeme d'enregistrement comportant un tel transducteur
EP0048149B1 (fr) 1980-09-12 1983-11-30 University of Illinois Foundation Antibiotiques, dérivés de ceux-ci, procédé de leur extraction et compositions contenant ceux-ci
US4782135A (en) 1980-09-12 1988-11-01 Board Of Trustees, University Of Illinois Composition of matter and process
US5137870A (en) 1980-09-12 1992-08-11 The Board Of Trustees Of The University Of Illinois Didemnins and nordidemnins
US4493796A (en) 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
US4950649A (en) 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
US4548814A (en) 1980-12-18 1985-10-22 The Board Of Trustees Of The University Of Illinois Composition of matter and process
JPS5922518A (ja) 1982-07-29 1984-02-04 余合住金産業株式会社 洋服タンス
IT1153974B (it) 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US4855086A (en) 1982-10-15 1989-08-08 Burroughs Wellcome Co. Novel pesticides, preparation and use
US4537883A (en) 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
JPS59225189A (ja) 1983-06-03 1984-12-18 Shionogi & Co Ltd キノナミン誘導体およびその製造法
US4631149A (en) 1983-07-25 1986-12-23 University Of Illinois Antiviral eudistomins from a marine tunicate
JPS6084288A (ja) 1983-10-13 1985-05-13 Shionogi & Co Ltd シアノキノナミンアセテ−ト類およびその製造法
US4567253A (en) 1984-02-03 1986-01-28 Tony Durst 2-Substituted derivatives of podophyllotoxin and etoposide
JPS61109717A (ja) 1984-11-02 1986-05-28 Teruhiko Beppu 抗腫瘍剤
ATE68186T1 (de) 1984-12-28 1991-10-15 Conpharm Ab Verwendung von podophyllotoxin und dessen derivaten.
US4644072A (en) 1985-04-12 1987-02-17 Bristol-Myers Company Intermediates for the production of epipodophyllotoxin and related compounds and processes for the preparation and use thereof
EP0220453B1 (fr) 1985-09-20 1992-04-15 Cernitin S.A. Application d'extraits de pollen de plantes à la préparation de compositions pharmaceutiques ralentissant la croissance de cellules tumorales et procédé pour leur préparation
US4731377A (en) 1986-01-31 1988-03-15 Harbor Branch Oceanographic Institute, Inc. Antitumor cyclic peroxides
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
DE3774435D1 (de) 1986-06-09 1991-12-12 Univ Pennsylvania Ekteinascidine 729, 743, 745, 759a, 759b and 770.
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US4816450A (en) 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
US4737510A (en) 1986-09-30 1988-04-12 The Board Of Trustees Of The University Of Illinois Bioactive metabolites from the caribbean sponge agelas coniferin
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US4847246A (en) 1987-09-11 1989-07-11 Wilson George R Antiviral compositions derived from fireflies and their methods of use
FR2623504B1 (fr) 1987-11-25 1990-03-09 Adir Nouveaux derives n-(vinblastinoyl-23) d'acide amino-1 methylphosphonique, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
US5559145A (en) 1988-06-01 1996-09-24 Oxaco S.A. 1,2,4-trioxane derivatives
DE68903907T2 (de) 1988-09-05 1993-06-09 Sankyo Co Cyclisches peptid, seine herstellung und seine verwendung zur behandlung von cardiovasculaeren stoerungen.
WO1990005731A1 (fr) 1988-11-24 1990-05-31 University Of Queensland Macromolecules cytotoxiques
US5190876A (en) 1988-12-27 1993-03-02 Emory University Method of modifying cellular differentiation and function and compositions therefor
US5583160A (en) 1989-02-03 1996-12-10 The Biomembrane Institute Methylsphingosine used to treat apoptosis
CA2007507C (fr) 1989-02-03 1998-05-19 Yasuyuki Igarashi Sphingosine et n-methyl-sphingosine inhibiteurs de la croissance des cellules
US4948791A (en) 1989-04-10 1990-08-14 The Board Of Trustees Of The University Of Illinois Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
US20030148933A1 (en) 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
GB8922026D0 (en) 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US5053559A (en) 1989-12-29 1991-10-01 Oxaco S.A. Cleavage of 1,2,4-trioxanes
KR910014122A (ko) 1990-01-19 1991-08-31 디께다 가즈히꼬 에토포시드-2-디메틸아미노 화합물의 동결건조 제제
JPH0539283A (ja) 1991-01-31 1993-02-19 Suntory Ltd 新規物質Ｓ−５９９１７ａ及びその製造方法
US5721352A (en) 1991-02-19 1998-02-24 University Of Florida Research Foundation Entomopoxvirus expression system
DE4120327A1 (de) 1991-06-20 1992-12-24 Basf Ag Neue peptide, ihre herstellung und verwendung
US5336669A (en) 1991-12-10 1994-08-09 Erbamont, Inc. Cyclophosphamide monohydrate and lactose
JPH05247055A (ja) 1992-03-03 1993-09-24 Meiji Seika Kaisha Ltd スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤
GB9206244D0 (en) 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
GB9212000D0 (en) 1992-06-05 1992-07-15 Univ Madrid Complutense New synthetic antitumoral compound
CA2140653A1 (fr) 1992-08-12 1994-03-03 Irene Abraham Inhibiteurs de la proteine kinase et composes connexes combines avec le taxol
US5756734A (en) 1992-09-11 1998-05-26 Pharmamar, S.A. Crambescidins: new antiviral and cytotoxic compounds from the sponge crambe crambe
ES2059259B1 (es) 1992-09-22 1995-10-01 Pharma Mar S A Pharmar Procedimiento de obtencion de nuevos areno (e)indoles utiles como intermedios en la sintesis de productos con actividad antitumoral.
US5580871A (en) 1992-11-20 1996-12-03 The Dupont Merck Pharmaceutical Company 4-Heteroaryl- 1,4-dihydropyridine compounds with calcium agonist and alpha1 -antagonist activity
US6274551B1 (en) 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
GB9302044D0 (en) 1993-02-03 1993-03-24 Pharma Mar Sa Cytotoxic compounds i
GB9302046D0 (en) 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
US5569757A (en) 1993-03-30 1996-10-29 Rinehart; Kenneth L. 9-deazaadenosine and its 5'-α-D-glycopyranoside isolated from the cyanobacterium anabaena affinis strain VS-1
GB9308111D0 (en) 1993-04-20 1993-06-02 Pharma Gen S A Active compound from a stonge
US5556777A (en) 1993-09-09 1996-09-17 Pharmamar, S.A. Immunosuppressive pharmaceutical compositions new biological activity from a marine agrobacterium sp.
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US5462726A (en) 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
US5514708A (en) 1994-02-18 1996-05-07 Pharmamar, S.A. Cytotoxic metabolites from Myriapora truncata
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
US5681813A (en) 1994-04-06 1997-10-28 Pharma Mar, S.A. Thiodepsipeptide isolated from a marine actinomycete
ES2100124B1 (es) 1994-08-01 1998-04-01 Pharma Mar Sa Perfeccionamientos introducidos en la p.i. 9401697 por terpeno-quinonas con actividad antitumoral.
US5514705A (en) 1994-09-07 1996-05-07 Pharmamar, S.A. Epidioxymanadic acids A and B
US5523456A (en) 1994-09-29 1996-06-04 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
GB9422946D0 (en) 1994-11-14 1995-01-04 Univ Salamanca Antineoplastic cyclolignan derivatives
GB9422947D0 (en) 1994-11-14 1995-01-04 Univ Salamanca Immunosuppressive cyclolignan derivatives
GB9504662D0 (en) 1995-03-08 1995-04-26 Pharma Mar Sa Antitumour isocoumarins
US20010039041A1 (en) 1995-06-07 2001-11-08 Pharma Mar, S.A. Immunosuppressive sesbanimide compositions and methods of treatment using same
US5661175A (en) 1995-06-20 1997-08-26 Kashman; Yoel Hemiasterlin and geodiamolide TA
US5852033A (en) 1995-06-29 1998-12-22 Pharma Mar, S.A. Methods of treatment using lamellarin-class alkaloids
ES2102322B1 (es) 1995-07-13 1998-03-01 Pharma Mar Sa Procedimiento de preparacion de didemnina a.
US5681847A (en) 1995-12-05 1997-10-28 Harbor Branch Oceanographic Institution, Inc. Methods of using discodermolide compounds
EP0821068A3 (fr) 1996-03-29 1999-06-02 Rohm And Haas Company Sphinogolipides et procédé pour ceux-ci
GB9608010D0 (en) 1996-04-18 1996-06-19 Pharma Mar Sa Trunkamide A
US6156724A (en) 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
DE69735583T2 (de) 1996-10-24 2007-04-05 The Board Of Trustees Of The University Of Illinois, Urbana Semisynthetisches verfahren zur herstellung von didemninanalogen
US6380156B1 (en) 1996-10-24 2002-04-30 The Board Of Trustees Of The University Of Illnois Total synthesis of the amino hip analogue of didemnin A
GB9622427D0 (en) 1996-10-28 1997-01-08 Pharma Mar Sa Antimalarial drugs
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
US6034058A (en) 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
US6800661B1 (en) 1997-04-15 2004-10-05 Board Of Trustees Of The University Of Illinois Spisulosine compounds
US6107520A (en) 1997-04-15 2000-08-22 The Board Of Trustees Of The University Of Illinois Spisulosine compounds
USRE38793E1 (en) 1997-04-15 2005-09-06 Rinehart Kenneth L Spisulosine compounds
US6028077A (en) 1997-04-15 2000-02-22 Rinehart; Kenneth L. Crambescidin compounds
AUPO656597A0 (en) 1997-05-02 1997-05-29 Australian National University, The Preparation of therapeutic compounds
US6030943A (en) 1997-05-07 2000-02-29 Crumb; William J. Dehydrodidemnin B as an L-type calcium channel enhancer
GB9723206D0 (en) 1997-11-03 1998-01-07 Inst Biomar Sa New cytotoxic pyridoacridine alkaloids
GB9727301D0 (en) 1997-12-23 1998-02-25 Inst Biomar Sa Asmarine A and B: New cytotoxic alkaloids
US6420357B1 (en) 1997-12-23 2002-07-16 Instituto Biomar, S.A. Cytotoxic alkaloid derivatives including Asmarine A and B isolated from a sponge
GB9801741D0 (en) 1998-01-27 1998-03-25 Inst Biomar Sa New cytotoxic tris (oxazole)-containing macrolides
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
DE69936845T2 (de) 1998-04-06 2008-05-08 The Board Of Trustees Of The University Of Illinois, Urbana Halbsynthetische ectein-ascidine
US6656948B2 (en) 1998-04-29 2003-12-02 Universidad Complutense De Madrid Cytotoxic compounds: derivatives of the pyrido[2,3,4-kl]acridine ring system
KR100603220B1 (ko) 1998-05-05 2006-07-20 파르마 마르, 에스.에이. 고착성 해양동물의 배양방법
ATE289810T1 (de) * 1998-05-11 2005-03-15 Pharma Mar Sa Ecteinascidinderivate
GB9810998D0 (en) 1998-05-21 1998-07-22 Univ Madrid Complutense Antitumour 1,5-diazaanthraquinones
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
GB9821975D0 (en) 1998-10-08 1998-12-02 Pharma Mar Sa New cytotoxic alkaloids
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
GB9918178D0 (en) 2000-05-15 1999-10-06 Pharma Mar Sa Synthetic methods
GB9915069D0 (en) 1999-06-28 1999-08-25 Inst Biomar Sa New indolocarbazole alkaloids from a marine actinomycete
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
MXPA02004862A (es) 1999-11-15 2003-01-28 Pharma Mar Sa Tratamiento de aplidina para canceres.
JP2003520801A (ja) 2000-01-19 2003-07-08 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク サフラマイシン−エクテイナシジン系列の化合物、それらの使用及び合成
GB0002952D0 (en) 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
ATE316524T1 (de) 2000-02-16 2006-02-15 Pharma Mar Sa Oxy- und aminosubstituierte tetrahydrofurylderivate mit antitumoraktivität
US20030187075A1 (en) 2000-03-20 2003-10-02 Junichi Tanaka Keith Sponge antitumor compounds
RU2323000C2 (ru) 2000-04-07 2008-04-27 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Аналоги тамандарина и дидемнина и способы их получения и применения
US6509315B1 (en) 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
US7919493B2 (en) 2000-04-12 2011-04-05 Pharma Mar, S.A. Anititumoral ecteinascidin derivatives
KR100886496B1 (ko) * 2000-04-12 2009-03-05 파르마 마르, 에스.에이. 항종양성 엑티나시딘 유도체
GB0010799D0 (en) 2000-05-04 2000-06-28 Inst Biomar Sa Stolonoxides
US7420051B2 (en) 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
GB0011927D0 (en) 2000-05-17 2000-07-05 Inst Biomar Sa New use of citreamicins
JP2003535868A (ja) 2000-06-06 2003-12-02 ファルマ・マール・ソシエダード・アノニマ 抗腫瘍化合物
GB0016020D0 (en) 2000-06-29 2000-08-23 Inst Biomar Sa New polyciclic xanthones and their use
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
PT1299388E (pt) 2000-07-11 2009-08-13 Pharma Mar Sa Derivados de variolina como agentes anticancerígenos
WO2002005868A2 (fr) 2000-07-13 2002-01-24 Transurgical, Inc. Procedes et appareil de traitements thermiques a application d'energie focalisee
GB0019117D0 (en) 2000-08-03 2000-09-27 Univ Barcelona Derivatives of variolin B
PL361179A1 (en) 2000-10-12 2004-09-20 Pharma Mar S.A. Treatment of cancers
DE60111858T2 (de) 2000-10-12 2006-04-20 Pharma Mar, S.A., Tres Cantos BEHANDLUNG VON KREBSERKRANKUNGEN mit APLIDIN IN KOMBINATION MIT CARNITIN ODER ACETYLCARNITIN
AU2002210749B2 (en) 2000-10-31 2006-12-21 Pharma Mar, S.A. Kahalalide F formulation
ATE495793T1 (de) 2000-11-06 2011-02-15 Pharma Mar Sa Antitumorzusammensetzungen welche ecteinascidin 743 enthalten
GB0030417D0 (en) 2000-12-13 2001-01-24 Pharma Mar Sa An anticancer lead compound isolated from a New Zealand ascidian
WO2002058688A1 (fr) 2001-01-24 2002-08-01 Mestex Ag Utilisation de substances neurotoxiques pour la production d'un agent servant a traiter les douleurs articulaires
JP2004521122A (ja) 2001-01-25 2004-07-15 ブリストル−マイヤーズ　スクイブ　カンパニー エポチロン類似体の非経口製剤
EP1360337A1 (fr) 2001-02-09 2003-11-12 The Regents Of The University Of California Composes de la famille de l'ecteinascidine: compositions et procedes
GB0105745D0 (en) 2001-03-08 2001-04-25 Pharma Gen S A Immobilisation of ligands
GB0108234D0 (en) 2001-04-02 2001-05-23 Pharma Mar Sa Process for producing trunkamide A compounds
GB0116966D0 (en) 2001-07-11 2001-09-05 Pharma Mar Sa Anittumoral compounds
GB0117402D0 (en) 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0119243D0 (en) 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
HUP0401903A3 (en) 2001-10-19 2008-07-28 Pharma Mar Improved use of et-743 in cancer thereapy
CA2462639A1 (fr) 2001-10-19 2003-04-24 Pharma Mar, S.A. Composes a base de kahalalide utilisables en therapie anticancereuse
US20050054555A1 (en) 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
US20050004012A1 (en) 2001-10-19 2005-01-06 Ramon Mangues Use of aplidine for the treatment of pancreatic cancer
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
US20040019027A1 (en) 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0217638D0 (en) 2002-07-30 2002-09-11 Pharma Mar Sa Total synthesis of myriaporones
PT2357006E (pt) 2002-07-31 2016-01-22 Seattle Genetics Inc Conjugados de fármacos e sua utilização para tratamento do cancro, de uma doença autoimune ou de uma doença infeciosa
GB0218813D0 (en) 2002-08-13 2002-09-18 Pharma Mar Sa DNA sequences from an endosymbiont and their uses
GB0218816D0 (en) 2002-08-13 2002-09-18 Pharma Mar Sa Antitumoral analogs of lamellarins
US20040033940A1 (en) 2002-08-16 2004-02-19 Pharma Mar, S.A. Cyclic hepta-peptide derivative from colonial ascidians, lissoclinum SP
MXPA05004133A (es) 2002-10-18 2005-10-05 Pharma Mar Sau Nuevos compuestos antitumorales.
GB0304367D0 (en) 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
GB0229793D0 (en) 2002-12-20 2003-01-29 Pharma Mar Sa The gene cluster involved in safracin biosynthesis and its uses for genetic engineering
ATE472338T1 (de) 2003-02-20 2010-07-15 Seattle Genetics Inc Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs
GB0303940D0 (en) 2003-02-20 2003-03-26 Pharma Mar Sau Solid phase synthesis of antitumoral compounds
US7507708B2 (en) 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
RU2341283C2 (ru) 2003-03-12 2008-12-20 Фарма Мар, С.А. Усовершенствованное лечение опухолей
SI1603584T1 (sl) 2003-03-12 2009-02-28 Dana Farber Cancer Inst Inc Aplidin za zdravljenje multiple mieloma
WO2004084812A2 (fr) 2003-03-21 2004-10-07 Joullie Madeleine M Analogues de « tamandarin », fragments associes et leurs methodes d'elaboration et d'utilisation
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
GB0312407D0 (en) 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
KR20060031809A (ko) 2003-06-09 2006-04-13 더 리젠츠 오브 더 유니버시티 오브 미시간 암 치료 및 진단용 조성물 및 방법
GB0314726D0 (en) 2003-06-24 2003-07-30 Inst Biomar Sa New cytotoxic depsipeptides
WO2005014574A1 (fr) 2003-07-25 2005-02-17 Novartis Ag Lactames substitues et utilisation de ceux-ci en tant qu'agents anti-cancereux
GB0321066D0 (en) 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
CA2540868A1 (fr) 2003-10-09 2005-04-21 Abbott Laboratories Derives de pyrrolidinyle- uree utilises comme inhibiteurs de l'angiogenese
GB0324201D0 (en) 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
RS50692B (sr) 2003-11-13 2010-06-30 Pharma Mar S.A.U. Kombinacija et-743 sa prolekovima 5-fluorouracila za lečenje kancera
JP2007511509A (ja) * 2003-11-14 2007-05-10 ファルマ・マール・ソシエダード・アノニマ Ｅｔ−７４３およびパクリタキセルの使用を含むガンの併用療法
GB0326486D0 (en) 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
DE102004011809A1 (de) 2004-03-11 2005-09-29 Robert Bosch Gmbh Magnetsensoranordnung
GB0408958D0 (en) 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds
WO2005118584A2 (fr) 2004-05-26 2005-12-15 Axys Pharmaceuticals, Inc. Nouveaux analogues de saframycine utilises en tant qu'agents therapeutiques
US7446196B2 (en) 2004-06-03 2008-11-04 Kosan Biosciences, Incorporated Leptomycin compounds
EP1768671A2 (fr) 2004-07-09 2007-04-04 Pharma Mar, S.A. Compositions contenant d'ecteinascidin et undisaccharide pour le traitement du cancer chez les patients ayant un faible niveau de brca1
WO2006035244A2 (fr) 2004-09-29 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Agents anti-inflammatoires
MX2007004744A (es) 2004-10-26 2007-10-23 Pharma Mar Sa Doxorubicina lipos??mica pegilada en combinacion con ecteinascidina 743.
RS50510B (sr) 2004-10-29 2010-03-02 Pharma Mar S.A., Sociedad Unipersonal Formulacije koje sadrže ekteinascidin i disaharid
WO2006060533A2 (fr) 2004-12-01 2006-06-08 Genentech, Inc. Conjugues medicament anticorps et procedes correspondants
WO2006066183A2 (fr) 2004-12-16 2006-06-22 Axys Pharmaceuticals, Inc. Nouveaux analogues de saframycine utilises en tant qu'agents therapeutiques
MX2007013683A (es) 2005-05-03 2007-12-03 Pharma Mar Sa Tetrahidropirimidinas antitumorales.
GB0515673D0 (en) 2005-08-01 2005-09-07 Pharma Mar Sa Antitumoral compounds
WO2007014971A2 (fr) 2005-08-02 2007-02-08 Pharma Mar, S.A. Genes jouant un role dans la biosynthese de la thiocoraline et production heterologue de cette derniere
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
GB0523098D0 (en) 2005-11-14 2005-12-21 Pharma Mar Sa Antitumoral compounds
ES2361566T3 (es) 2005-11-25 2011-06-20 Pharma Mar S.A., Sociedad Unipersonal Uso de inhibidores de parp-1.
ES2276629B1 (es) 2005-12-15 2009-04-01 Pharma Mar, S.A. Compuestos antitumorales.
ES2288107B1 (es) 2006-01-27 2008-11-01 Fundacion Imabis Instituto Mediterraneo Para El Avance De La Biotecnologia Y La Investigacion Sanita Derivados aciclicos saturados e insaturados de cadena larga de sulfamidas como activadores especificos de receptores ppar-alfa.
RU2481853C2 (ru) 2006-02-28 2013-05-20 Фарма Мар, С.А. Улучшенные способы лечения опухолей
JP2009536956A (ja) 2006-05-12 2009-10-22 ファルマ・マール・ソシエダード・アノニマ 抗癌治療法
EP1864682A1 (fr) 2006-06-09 2007-12-12 Sanofi-Aventis Dérivés de la Leptomycine
ES2371942T3 (es) 2006-06-16 2012-01-11 Pharma Mar, S.A. Compuestos antitumorales de dihidropiran-2-ona.
CA2703024A1 (fr) 2007-10-19 2009-04-23 Giuseppe Longo Sorbello Traitements antitumoraux ameliores
MX2010004259A (es) 2007-10-19 2010-08-31 Pharma Mar Sa Tratamientos antitumorales mejorados.
WO2009050303A1 (fr) 2007-10-19 2009-04-23 Pharma Mar, S.A. Marqueurs moléculaires pronostiques pour le traitement par et-743
CN101932592B (zh) 2007-12-14 2014-02-26 马尔药品公司 抗肿瘤化合物
SG170779A1 (en) 2007-12-20 2011-05-30 Pharma Mar Sa Antitumoral compounds
EP2252315A1 (fr) 2008-01-30 2010-11-24 Pharma Mar, S.A. Traitements antitumoraux améliorés
EP2262523A1 (fr) 2008-03-07 2010-12-22 Pharma Mar S.A. Traitements améliorés contre le cancer
JP2011513370A (ja) 2008-03-07 2011-04-28 ファルマ・マール・ソシエダード・アノニマ 改善された抗腫瘍治療法
US20110070232A1 (en) 2008-05-16 2011-03-24 Pharma Mar, S.A. Combination Therapy with an Antitumor Alkaloid
KR20110028454A (ko) 2008-05-16 2011-03-18 파르마 마르 에스.에이. 다발성 골수종 치료법
CN104230831B (zh) 2008-05-23 2016-08-24 惠氏有限责任公司 作为PI3激酶和mTOR抑制剂的三嗪化合物
KR20110043653A (ko) 2008-07-03 2011-04-27 파르마 마르 에스.에이. 항종양 마크롤라이드
KR101667062B1 (ko) 2008-07-15 2016-10-17 제넨테크, 인크. 안트라시클린 유도체 접합체, 그의 제조 방법 및 항-종양 화합물로서의 그의 용도
AU2009272661A1 (en) 2008-07-17 2010-01-21 Pharma Mar, S.A. Anticancer compounds
WO2010070078A1 (fr) 2008-12-19 2010-06-24 Pharma Mar, S.A. Composés anticancéreux
WO2010149688A2 (fr) 2009-06-24 2010-12-29 Pharma Mar, S.A. Composés anticancéreux
SG185032A1 (en) 2010-04-27 2012-11-29 Pharma Mar Sa Anticancer steroidal lactones unsaturated in position 7 (8)
WO2011147828A1 (fr) 2010-05-25 2011-12-01 Pharma Mar, S.A. Procédé de synthèse pour la préparation de composés ecteinascidines
BR122017028566B1 (pt) 2010-11-12 2022-03-03 Pharma Mar, S.A. Uso de pm01183, ou um sal farmaceuticamente aceitável do mesmo, em combinação sinérgica com um antibiótico anticâncer e kit
DE102012211024B4 (de) 2012-06-27 2024-10-24 Robert Bosch Gmbh Verfahren zum Betreiben eines Fahrzeuges
JP5922518B2 (ja) 2012-07-20 2016-05-24 浜松ホトニクス株式会社 シンチレータパネル及び放射線検出器
GB201309807D0 (en) 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
CN109476645A (zh) 2016-07-14 2019-03-15 辉瑞大药厂 作为vanin-1酶抑制剂的新的嘧啶甲酰胺
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
TWI824043B (zh) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物

Also Published As

Publication number Publication date
MA44021A (fr) 2019-05-15
SA523440283B1 (ar) 2025-04-26
MD3615544T2 (ro) 2023-08-31
CN114736219A (zh) 2022-07-12
KR102510975B1 (ko) 2023-03-16
ES2741901T3 (es) 2020-02-12
KR20220109495A (ko) 2022-08-04
TW202344509A (zh) 2023-11-16
JP7422812B2 (ja) 2024-01-26
MX392829B (es) 2025-03-24
CN114751920B (zh) 2024-06-07
LT4101855T (lt) 2023-08-25
ES2944344T3 (es) 2023-06-20
JOP20190254A1 (ar) 2019-10-27
JP2023052597A (ja) 2023-04-11
HRP20191442T1 (hr) 2019-11-15
DK4047002T3 (da) 2023-05-01
US20210246146A1 (en) 2021-08-12
SI4101855T1 (sl) 2024-03-29
RS64174B1 (sr) 2023-05-31
MX392601B (es) 2025-03-24
US11713325B2 (en) 2023-08-01
ES2740073T3 (es) 2020-02-05
EP3615544B1 (fr) 2023-03-22
EP4047002A1 (fr) 2022-08-24
EP4047002B1 (fr) 2023-03-08
HUE045641T2 (hu) 2020-01-28
JP6501946B2 (ja) 2019-04-17
SI3395820T1 (sl) 2019-09-30
CN110621678B (zh) 2024-09-20
KR102491180B1 (ko) 2023-01-20
TW202202509A (zh) 2022-01-16
MX2019012812A (es) 2020-01-14
PH12019550224A1 (en) 2020-10-12
KR20210126791A (ko) 2021-10-20
AU2018260314B2 (en) 2021-12-09
EP4101855A1 (fr) 2022-12-14
HRP20191443T1 (hr) 2019-11-15
US20210070775A1 (en) 2021-03-11
MA44020B1 (fr) 2019-08-30
MD3395821T2 (ro) 2019-10-31
CA3061518A1 (fr) 2018-11-01
IL289963B2 (en) 2023-10-01
MD3395820T2 (ro) 2019-10-31
IL270153B1 (en) 2023-06-01
BR112019022282A2 (pt) 2020-05-19
TWI807411B (zh) 2023-07-01
SMT201900447T1 (it) 2019-09-09
HUE062157T2 (hu) 2023-10-28
HRP20231233T1 (hr) 2024-01-19
IL270153B2 (en) 2023-10-01
CY1126061T1 (el) 2023-11-15
DK3615544T3 (da) 2023-05-30
FI3615544T3 (fi) 2023-05-23
WO2018197663A1 (fr) 2018-11-01
ES2960063T3 (es) 2024-02-29
SI3615544T1 (sl) 2023-07-31
MY198004A (en) 2023-07-25
PT3395821T (pt) 2019-08-27
IL295044B1 (en) 2023-07-01
PL3395820T3 (pl) 2019-11-29
PL4101855T3 (pl) 2023-12-27
TN2019000210A1 (en) 2021-01-07
ZA201907119B (en) 2021-07-28
JP2018188431A (ja) 2018-11-29
CO2019011967A2 (es) 2020-02-18
HRP20230433T1 (hr) 2023-07-07
EP3395821A1 (fr) 2018-10-31
SMT202300343T1 (it) 2023-11-13
IL289963B1 (en) 2023-06-01
NZ797532A (en) 2025-06-27
CL2019003057A1 (es) 2020-02-21
JP2022130682A (ja) 2022-09-06
AU2018260314C1 (en) 2022-04-21
TN2019000211A1 (en) 2021-01-07
US11332480B2 (en) 2022-05-17
US10538535B2 (en) 2020-01-21
EP3615544A1 (fr) 2020-03-04
MD4047002T2 (ro) 2023-08-31
PT3395820T (pt) 2019-08-07
FI4101855T3 (fi) 2023-09-22
EP4101855B1 (fr) 2023-08-02
EP3395820A1 (fr) 2018-10-31
EP3395821B1 (fr) 2019-05-15
CN117865987A (zh) 2024-04-12
SI4047002T1 (sl) 2023-07-31
US20240166666A1 (en) 2024-05-23
SMT201900448T1 (it) 2019-09-09
RS64686B1 (sr) 2023-11-30
CN114736219B (zh) 2024-06-07
LT3615544T (lt) 2023-05-10
ES2944579T3 (es) 2023-06-22
JP7186723B2 (ja) 2022-12-09
TWI875118B (zh) 2025-03-01
AU2022200249C1 (en) 2022-06-23
CN114751920A (zh) 2022-07-15
LT4047002T (lt) 2023-05-10
MX2021016058A (es) 2022-02-03
DK4101855T3 (da) 2023-11-06
CY1121884T1 (el) 2020-10-14
CY1121885T1 (el) 2020-10-14
ME03467B (fr) 2020-01-20
KR20200012846A (ko) 2020-02-05
HK1255941B (en) 2020-04-29
AU2018260314A1 (en) 2019-10-31
NZ758490A (en) 2025-06-27
PL3615544T3 (pl) 2023-07-17
CN110621678A (zh) 2019-12-27
IL289963A (en) 2022-03-01
JP7490835B2 (ja) 2024-05-27
DK3395820T3 (da) 2019-08-12
AU2022200250C1 (en) 2022-06-23
TWI742273B (zh) 2021-10-11
DK3395821T3 (da) 2019-08-19
LT3395820T (lt) 2019-08-12
JP6501947B2 (ja) 2019-04-17
RS59173B1 (sr) 2019-10-31
HK1255938B (en) 2020-04-29
HUE046109T2 (hu) 2020-02-28
MD4101855T2 (ro) 2023-12-31
US11339180B2 (en) 2022-05-24
NZ797531A (en) 2025-06-27
US20220242883A1 (en) 2022-08-04
RS64200B1 (sr) 2023-06-30
MX2021016054A (es) 2022-06-01
HUE062032T2 (hu) 2023-09-28
PL4047002T3 (pl) 2023-07-24
EP3395820B1 (fr) 2019-05-15
JP2020517709A (ja) 2020-06-18
IL295044A (en) 2022-09-01
KR102492283B1 (ko) 2023-01-27
IL270153A (fr) 2019-12-31
HRP20230455T1 (hr) 2023-07-21
EP3615544B9 (fr) 2024-01-03
JP2018188432A (ja) 2018-11-29
SG10201913300YA (en) 2020-03-30
US12384800B2 (en) 2025-08-12
LT3395821T (lt) 2019-08-12
FI4047002T3 (fi) 2023-05-22
AU2022200249B1 (en) 2022-02-10
EP4101855B9 (fr) 2024-01-03
TW201906850A (zh) 2019-02-16
HUE063736T2 (hu) 2024-01-28
ME03466B (fr) 2020-01-20
US20180312529A1 (en) 2018-11-01
PL3395821T3 (pl) 2019-10-31
MA44021B1 (fr) 2019-08-30
ECSP19083967A (es) 2019-12-27
SG11201909841RA (en) 2019-11-28
AU2022201657A1 (en) 2022-03-31
SI3395821T1 (sl) 2019-09-30
SMT202300160T1 (it) 2023-07-20
UY37706A (es) 2018-11-30
IL295044B2 (en) 2023-11-01
SMT202300169T1 (it) 2023-07-20
RS59174B1 (sr) 2019-10-31
AU2022200250B1 (en) 2022-02-10

Similar Documents

Publication Publication Date Title
EP3720430A4 (fr) Composés benzocarbonyle
EP3691623A4 (fr) Composés de benzosulfonyle
MA44020A (fr) Composés antitumoraux
MA47131A (fr) Composés benzyl-amide phosphodiamide antiviraux
MA49701A (fr) Composés immunomodulateurs
EP3836923A4 (fr) Composés pyrrolo-dipyridine
MA52948A (fr) Composés
EP3532069A4 (fr) Composés aryl-amide phosphodiamide antiviraux
MA41614A (fr) Composés antiviraux
EP3474845A4 (fr) Composés immunomodulateurs
MA42293A (fr) Composés antibactériens
MA51669A (fr) Composés
MA53003A (fr) Composés
EP3464336A4 (fr) Composés
EP3728289A4 (fr) Composés optimisés
MA49621A (fr) Composés bifonctionnels
EP3718545A4 (fr) Agent antitumoral
MA50504A (fr) Composés antibactériens
EP3405455A4 (fr) Composés de 2-oxindole
MA52946A (fr) Composés
EP3713941A4 (fr) Composés de pyrazolopyridinone
EP3717483A4 (fr) Composés de pyrazolopyridinone
MA49522A (fr) Nouveaux composés de quinoléinone
MA49885A (fr) Composés macrocycliques
EP3504269A4 (fr) Composés de fluoroélastomère